KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

The biological functions and mechanisms of oncogenic KRAS(G12D) (KRAS*) in resistance to immune checkpoint blockade (ICB) therapy are not fully understood. We demonstrate that KRAS* represses the expression of interferon regulatory factor 2 (IRF2), which in turn directly represses CXCL3 expression....

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Cell
Hoofdauteurs: Liao, Wenting, Overman, Michael J., Boutin, Adam T., Shang, Xiaoying, Zhao, Di, Dey, Prasenjit, Li, Jiexi, Wang, Guocan, Lan, Zhengdao, Li, Jun, Tang, Ming, Jiang, Shan, Ma, Xingdi, Chen, Peiwen, Katkhuda, Riham, Korphaisarn, Krittiya, Chakravarti, Deepavali, Chang, Andrew, Spring, Denise J., Chang, Qing, Zhang, Jianhua, Maru, Dipen M., Maeda, Dean Y., Zebala, John A., Kopetz, Scott, Alan Wang, Y., DePinho, Ronald A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2019
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6467776/
https://ncbi.nlm.nih.gov/pubmed/30905761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2019.02.008
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items